This opportunity funds research to develop innovative antibacterial and antifungal agents targeting antimicrobial resistant pathogens such as CRAB, CRE, MRSA, and drug-resistant fungi. Proposals must meet WHO innovation criteria and focus on accelerating clinical testing of candidates. Phage-therapies are excluded. The goal is to enhance therapeutic options and reduce disease burden caused by antimicrobial resistance.
Eligible applicants include legal entities from EU, associated countries, and the USA. Applicants must comply with admissibility, financial, and operational conditions outlined in the Horizon Europe Work Programme annexes. Specific eligibility details are in the programme guide and annexes.
